Safety monitoring in treatment with biological agents of patients with chronicinflammatory arthritis
General Medicine, 2024, 26(5), 48-53.
S. Stoilova1, M. Geneva-Popova2, G. Tsigarovski3, D. Mileva-Nikolova3
1 Rheumatology Clinic, UMHAT „Sv. Georgi“ ‒ Plovdiv
2 Department of Propedeutics of Internal Diseases, Medical Faculty, Medical University ‒ Plovdiv
3 Department of Urology and General Practice, Medical Faculty, Medical University ‒ Plovdiv
Abstract. Safety monitoring identifies and evaluates potential side effects of the treatment in order to prevent the occurrence of future ones by improving the patient problem-solving abilities related to their safety. The use of biologic disease-modifying antirheumatic drugs is associated with recommendations for close disease monitoring. To ensure their safe implementation, the existing recommendations for the management of chronic inflammatory arthritis require monitoring of related safety issues, which can be overcome through patient education. Safety monitoring includes various aspects: to patients, on the one hand, and to specialized rheumatology team on the other (most commonly a physician, health care professional – nurse, etc.), as well as active involvement of primary care health professionals.
Key words: biologic disease-modifying antirheumatic drugs, safety monitoring, chronic inflammatory arthritis, nursing, primary care
Address for correspondence: S. Stoilova, e-mail: ef_i@abv.bg